Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin

dc.authorid0000-0003-1985-616X
dc.authorscopusid16315443300
dc.authorscopusid24366172600
dc.authorscopusid16315694300
dc.authorscopusid10144122400
dc.authorscopusid57222618405
dc.authorscopusid6602411427
dc.authorscopusid12143697500
dc.authorwosidDede, Fuat/Y-1079-2018
dc.authorwosidceliker, alpay/O-6067-2019
dc.authorwosidceliker, alpay/H-1830-2016
dc.contributor.authorErdim, Refik
dc.contributor.authorÇeliker, Aydın
dc.contributor.authorGemici, Gökmen
dc.contributor.authorTokay, Sena
dc.contributor.authorUelfer, Goezde
dc.contributor.authorDede, Fuat
dc.contributor.authorOktay, Ahmet
dc.date.accessioned2022-05-11T14:40:05Z
dc.date.available2022-05-11T14:40:05Z
dc.date.issued2009
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractThe aim of the study was to investigate the role of cTnT for the prediction of long term cardiac dysfunction after epirubicin-containing adjuvant chemotherapy for breast cancer. The study group comprised of 45 patients (all female; mean age 48 +/- 8 years), treated with epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer. Patients received either 4 cycles of cyclophosphamide plus epirubicin (90 mg/m(2)) (n=23; stage 2 breast cancer) or 6 cycles of cyclophosphamide plus epirubicin (75 mg/m(2)) plus fluorouracil (n=18; stage 3 breast cancer). Venous blood samples were drawn, before and 72 hours after, every cycle of chemotherapy for the measurement of cTnT. Cardiac assessment was carried out at baseline and 1 year after chemotherapy by clinical evaluation, electrocardiography, radio-nuclide ventriculography (RNV) and transthoracic echocardiography. All patients remained free of clinical heart failure during the study period. In 26 patients (63%), cTnT was elevated after chemotherapy. Mean left ventricular ejection fraction, assessed by RNV at baseline and one year after chemotherapy, were 61 +/- 8% and 56 +/- 7% (p < 0.0001). The sensitivity and specifity of cTnT for the detection of left ventricular systolic dysfunction at one year were 69% and 39% respectively. Echocardiographic examinations at baseline and one year after chemotherapy revealed a significant decrease in E/A ratio from 1.15 +/- 0.3 to 0.9 +/- 0.2 in cTnT positive patients, suggesting diastolic dysfunction. In conclusion, elevated serum cTnT levels after epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer, predict future cardiac dysfunction with moderate sensitivity and poor specificity.
dc.identifier.doi10.2478/s11536-008-0093-z
dc.identifier.endpage330
dc.identifier.issn1895-1058
dc.identifier.issn1644-3640
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-67651095815
dc.identifier.scopusqualityN/A
dc.identifier.startpage327
dc.identifier.urihttps://doi.org/10.2478/s11536-008-0093-z
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8862
dc.identifier.volume4
dc.identifier.wosWOS:000267669000011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorGemici, Gökmen
dc.language.isoen
dc.publisherDe Gruyter Poland Sp Zoo
dc.relation.ispartofCentral European Journal of Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast cancer
dc.subjectChemotherapy
dc.subjectEpirubicin
dc.subjectCardiotoxicity
dc.subjectcTnT
dc.subjectAnthracycline-Induced Cardiotoxicity
dc.subjectAdjuvant Chemotherapy
dc.subjectDiastolic Function
dc.subjectChildhood-Cancer
dc.subjectLeukemia
dc.subjectSurvivors
dc.titleCardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8862.pdf
Boyut:
1.12 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text